Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL

The purpose of this study is to determine the proportion of participants who achieve undetectable measurable residual disease (uMRD) in previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Trial Details

NCT ID

NCT06849713

Phase

PHASE2

Sponsor

Massachusetts General Hospital

Status

RECRUITING

Cancer Type

Leukemia

Interventions

Zanubrutinib
Sonrotoclax
Obinutuzumab
Tacabrutideg

Locations (sample)

Boston, Massachusetts, United States|42.35843,-71.05977
New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

Participant must have CLL or SLL (WHO criteria).
Participant must require treatment according to iwCLL guidelines.
Participants must have no prior systemic therapy for CLL or SLL, except:
Prior local radiation for symptomatic disease is permitted.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →